GoAI
Get started
Atea Pharmaceuticals, Inc. logo

Atea Pharmaceuticals, Inc.

AVIR

NASDAQHealthcareBiotechnology

Open in GoAI

Regular session

$5.4376

+$0.0076 · +0.14%

Aug 24, 12:29 PM ET

AVIR company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

25

Expensive

Momentum

58

Neutral

Sentiment

54

Mixed

Risk resilience

60

Moderate Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Jean-Pierre Sommadossi
Listed since
Oct 30, 2020
Employees
55

Market position

Day range

Current $5.4376

52-week range

Current $5.4376

Open
$5.385
Previous close
$5.43
Volume
31.55K
0.09× average
Average volume
332.99K
Average daily volume
Market cap
435.16M USD
Beta
0.27
Market reference 1
50-day average
$4.7906
+13.51% above average
200-day average
$4.4936
+21.01% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
196.07M USD
EV / EBITDA
-1.19×
Earnings yield
-54.43%
Free cash flow yield
-45.38%

Profitability & efficiency

Return on equity
-57.49%
Return on assets
-50.23%
Return on invested capital
-63.02%

Financial health

Current ratio
7.82×

Financial statements

Income trends

Operating income

−180.89M USD+6.25%

Net income

−158.35M USD+5.96%
Income trends across reported periods171.51M USD38.98M USD−93.55M USD−226.08M USDOperating income, FY2021: 138.38M USDOperating income, FY2022: −130.65M USDOperating income, FY2023: −164.16M USDOperating income, FY2024: −192.95M USDOperating income, FY2025: −180.89M USDNet income, FY2021: 121.19M USDNet income, FY2022: −115.91M USDNet income, FY2023: −135.96M USDNet income, FY2024: −168.39M USDNet income, FY2025: −158.35M USDFY2021FY2022FY2023FY2024FY2025
Operating income FY2021 138.38M USD. Operating income FY2022 −130.65M USD. Operating income FY2023 −164.16M USD. Operating income FY2024 −192.95M USD. Operating income FY2025 −180.89M USD. Net income FY2021 121.19M USD. Net income FY2022 −115.91M USD. Net income FY2023 −135.96M USD. Net income FY2024 −168.39M USD. Net income FY2025 −158.35M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue————351.37M USD
Cost of goods sold—83.37M USD70.09M USD62.39M USD167.21M USD
Gross profit—−83.37M USD−70.09M USD−62.39M USD184.16M USD
Research and development148.02M USD145.4M USD132.84M USD88.84M USD167.21M USD
Selling, general, and administrative32.86M USD48.85M USD49.92M USD48.71M USD45.79M USD
Operating expenses180.89M USD109.58M USD94.07M USD68.26M USD45.79M USD
Interest income16.38M USD25.49M USD29.22M USD11.15M USD213K USD
Interest expense———11.15M USD—
Depreciation and amortization416K USD416K USD416K USD260K USD29K USD
Operating income−180.89M USD−192.95M USD−164.16M USD−130.65M USD138.38M USD
Net income−158.35M USD−168.39M USD−135.96M USD−115.91M USD121.19M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
64%
7 beats, 4 misses, 0 met estimates
Average EPS surprise
+5.69%
11 comparable reports
Latest EPS result
-0.41
Estimate -0.56 · Beat by 26.13%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.31-0.42-0.53-0.64Q1 '25MissQ2 '25BeatQ3 '25BeatQ4 '25MissQ1 '26MissQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 6, 2025: actual -0.4, estimate -0.35, surprise -14.29%, Miss. Q2 2025, reported May 12, 2025: actual -0.4, estimate -0.56, surprise +28.57%, Beat. Q3 2025, reported Aug 7, 2025: actual -0.44, estimate -0.46, surprise +4.35%, Beat. Q4 2025, reported Nov 12, 2025: actual -0.53, estimate -0.46, surprise -15.22%, Miss. Q1 2026, reported Mar 5, 2026: actual -0.57, estimate -0.49, surprise -16.33%, Miss. Q2 2026, reported May 12, 2026: actual -0.57, estimate -0.6, surprise +5.00%, Beat. Q3 2026, reported Aug 12, 2026: actual -0.41, estimate -0.555, surprise +26.13%, Beat. Q4 2026, reported Nov 11, 2026: actual —, estimate -0.51, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates54.36M36.67M18.98M1.28MQ1 '26EstimateQ2 '26EstimateQ3 '26EstimateQ4 '26Estimate
Q1 2026, reported Mar 5, 2026: actual —, estimate 1.51M USD, surprise —, Comparison unavailable. Q2 2026, reported May 12, 2026: actual —, estimate 22.42M USD, surprise —, Comparison unavailable. Q3 2026, reported Aug 12, 2026: actual —, estimate 33.03M USD, surprise —, Comparison unavailable. Q4 2026, reported Nov 11, 2026: actual —, estimate 50.45M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

4 ratings

Limited analyst sample: 4 ratings. Interpret the distribution with caution.

Strong buy00%
Buy125%
Hold250%
Sell125%
Strong sell00%

AVIR news

seekingalpha.com

Atea Pharmaceuticals, Inc. (AVIR) Q2 2026 Earnings Call Transcript

Atea Pharmaceuticals, Inc. (AVIR) Q2 2026 Earnings Call Transcript

Read source
marketbeat.com

Atea Pharmaceuticals Q2 Earnings Call Highlights

Atea Pharmaceuticals NASDAQ: AVIR reported positive top-line results from its Phase III C-BEYOND trial of bemnifosbuvir/ruzasvir for chronic hepatitis C virus, saying the study met its primary and secondary endpoints…

Read source
globenewswire.com

Atea Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

Phase 3 C-BEYOND Trial Met Primary and Secondary Endpoints, with a Short 8-week Duration for Patients Without Cirrhosis Supporting a Potential Best-in-Class Profile of BEM/RZR for Treatment of HCV

Read source
globenewswire.com

Atea Pharmaceuticals to Host Second Quarter 2026 Financial Results and Business Update Conference Call on August 12, 2026

BOSTON, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral…

Read source
globenewswire.com

Atea Pharmaceuticals Meets Both Its Primary and Secondary Endpoints in the Phase 3 C-BEYOND North America Trial Evaluating Bemnifosbuvir/Ruzasvir for Hepatitis C Virus

Bemnifosbuvir/Ruzasvir (BEM/RZR) Achieved its Primary Endpoint of Statistical Non-inferiority Compared to Sofosbuvir/Velpatasvir (SOF/VEL; Epclusa ® ), a Standard-of-Care, in First-Ever Successful Head-to-Head Trial in a…

Read source
globenewswire.com

Atea Pharmaceuticals Initiates First-in-Human Phase 1 Clinical Trial of AT-587 for the Treatment of Hepatitis E Virus

Phase 1 Study Designed to Evaluate the Safety, Tolerability and Pharmacokinetics of AT-587 in Healthy Volunteers AT-587 is a Potential First-in Class Treatment for Hepatitis E Virus, a Serious Liver Disease with No…

Read source

AVIR peers

Amgen Inc. logo

AMGN

Amgen Inc.

$441.01

+0.38%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.17

+0.03%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$547.77

-0.05%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$376.6

-0.58%

Sanofi logo

SNY

Sanofi

$45.602

-0.54%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$825.38

-1.04%

ETFs holding AVIR

Funds reporting this stock among their holdings, ordered by reported position size.

iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
9.76M
Weight
0.01%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$298.35-0.54%
Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
9.55M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$377.7-0.14%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
4.08M
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$243.69-0.75%
iShares Russell 2000 Value ETF logoiShares Russell 2000 Value ETFIWN
Market value
3.61M
Weight
0.02%
AUM
14.66B USD
Expense ratio
0.24%
Price / 1D
$224.24-0.26%
iShares Biotechnology ETF logoiShares Biotechnology ETFIBB
Market value
2.6M
Weight
0.02%
AUM
10.75B USD
Expense ratio
0.44%
Price / 1D
$211.89-0.78%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
1.87M
Weight
0.01%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$120.62-0.52%
Schwab U.S. Small-Cap ETF logoSchwab U.S. Small-Cap ETFSCHA
Market value
1.86M
Weight
0.01%
AUM
23.1B USD
Expense ratio
0.03%
Price / 1D
$34.51-0.93%
Dimensional - US Small Cap ETF logoDimensional - US Small Cap ETFDFAS
Market value
1.43M
Weight
0.01%
AUM
15.92B USD
Expense ratio
0.26%
Price / 1D
$82.62-0.48%

Continue in GoAI

Research AVIR

research.disclaimer